The Board of Directors of Mangalam Drugs and Organics Limited, in its meeting held on March 26, 2026, approved the appointment of Ms. Shweta Patel as the Company Secretary, Compliance Officer, and Key Managerial Personnel, effective April 1, 2026. This management update follows the resignation of the previous Company Secretary, Ms. Anuradha Pandey, which was accepted in January 2026. Additionally, the board noted the transitions in its leadership team following the retirement of CFO Mr. Ajay Samant earlier in the year.

The company recently secured a significant repeat export order valued at approximately ₹15 Crore for Anti-Malarial Active Pharmaceutical Ingredients (API) from an international client, expected to be executed within early 2026. Despite this operational win, Mangalam Drugs faced financial stress in late 2025, leading to defaults on bank loan obligations totaling ₹765.19 Lacs to Bank of Maharashtra and Bank of Baroda. The company attributed these challenges to the discontinuation of US Aid funding and a reduction in global orders for Malaria, TB, and HIV treatments. In response, the management is actively pursuing a debt restructuring plan and has received NCLT approval for a merger scheme involving Mangalam Laboratories Private Limited and Shri JB Pharma Private Limited to consolidate operations.

For the last reported quarter ended December 31, 2025, the company’s financial performance remained under pressure. Revenue from operations for Q3 FY26 stood at ₹58.49 Crore, representing an 18.07% increase from the ₹49.54 Crore recorded in the preceding quarter (Q2 FY26) but a sharp 34.07% decline from ₹88.71 Crore in the corresponding quarter of the previous year (Q3 FY25). The company reported a net loss of ₹9.84 Crore for the quarter, widening from a loss of ₹7.35 Crore in Q2 FY26 and a significant reversal from the net profit of ₹1.29 Crore in Q3 FY25. As of December 2025, the promoter holding in the company decreased to 35.64% from 50.30% in the previous quarter, while retail investors hold a majority stake of 64.22%. No major institutional or famous individual investors were reported to hold significant stakes during this period.